Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YSCH-01 in advanced solid tumors
NCT05180851Phase 1Unknown
- Sponsor
- Shanghai Fengxian District Central Hospital
- Start
- Nov 2021
- Primary completion
- May 2023
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of recombinant L-IFN adenovirus in solid tumor, sponsored by Shanghai Fengxian District Central Hospital. Primary endpoints: Dose Limiting Toxicities at 28 days and Adverse Events at 6 months. Status: unknown.
02
Drugs
recombinant L-IFN adenovirus
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05180851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05180851.